MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or metastatic urothelial carcinoma (UC), the most common f
MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch
GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.
Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.